1. Bonafe L, Giunta C, Hasler CC, Janner M, Kraenzlin ME, Link B et al. Osteogenesis imperfecta: Klnik, Diagnose und Management vom Kindes- bis Erwachsenenalter. Schweiz Med Forum 2013; 13(46):925-931.
  2. Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A et al. Osteogenesis imperfecta. Nat Rev Dis Primers 2017; 3:17052.
  3. Martin E, Shapiro JR. Osteogenesis imperfecta:epidemiology and pathophysiology. Curr Osteoporos Rep 2007; 5(3):91-97.
  4. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet 2016; 387(10028):1657-1671.
  5. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363(9418):1377-1385.
  6. Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A 2015; 167A(12):2869-2892.
  7. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osterogenesis imperfecta. J Med Genet 1979;(16):-101.
  8. Bregou BA, Aubry-Rozier B, Bonafe L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly 2016; 146:w14322.
  9. van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 2014; 164A(6):1470-1481.
  10. Rohrbach M, Giunta C. Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings. Am J Med Genet C Semin Med Genet 2012; 160C(3):175-189.
  11. Cundy T. Recent advances in osteogenesis imperfecta. Calcif Tissue Int 2012; 90(6):439-449.
  12. van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet 2012; 20(1):11-19.
  13. van Dijk FS, Dalgleish R, Malfait F, Maugeri A, Rusinska A, Semler O et al. Clinical utility gene card for: osteogenesis imperfecta. Eur J Hum Genet 2013; 21(6).
  14. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc 2017; 10:145-155.
  15. Rauch F, Travers R, Plotkin H, and Glorieux FH. The effects of intravenous pamidronate an the bone tissue of children and adolescents with osteogenesis imprefecta. J Clin Invest 2003; 110:1293-1299.
  16. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008;(4):CD005088.
  17. Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH et al. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. J Bone Miner Res 2015; 30(12):2150-2157.
  18. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2016; 10:CD005088.
  19. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20(5):758-763.
  20. Shi CG, Zhang Y, Yuan W. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis. Am J Ther 2016; 23(3):e894-e904.
  21. Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, van Dijk AT, Sakkers RJ et al. Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review. Horm Res Paediatr 2015; 84(1):26-42.
  22. Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S et al. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone 2016; 87:11-18.
  23. Anam EA, Rauch F, Glorieux FH, Fassier F, Hamdy R. Osteotomy Healing in Children With Osteogenesis Imperfecta Receiving Bisphosphonate Treatment. J Bone Miner Res 2015; 30(8):1362-1368.
  24. Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382(9902):1424-1432.
  25. Kumar C, Panigrahi I, Somasekhara AA, Meena BL, Khandelwal N. Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children. J Pediatr Endocrinol Metab 2016; 29(8):947-952.
  26. Idolazzi L, Fassio A, Viapiana O, Rossini M, Adami G, Bertoldo F et al. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Bone 2017; 103:144-149.
  28. Rauch F, Plotkin H, Travers R, Zeitlin L, and Glorieux FH. Osteogenesis Imperfecta Types 1, 3 and 4: Effect of Pamidronate Therapy on Bone and Mineral Metabolism. The Journal of Clinical Endocrinology & Metabolism 2003; 88:986-992.
  29. Meier C, Uebelhart B, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari HA, Frey D et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly 2017; 147:w14484.
  30. Biggin A, Zheng L, Briody JN, Coorey CP, Munns CF. The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta. Horm Res Paediatr 2015; 83(3):183-189.
  31. Biggin A, Briody JN, Ormshaw E, Wong KK, Bennetts BH, Munns CF. Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen. Horm Res Paediatr 2014; 81(3):204-210.
  32. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006; 91(4):1268-1274.
  33. Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta – a first prospective trial. J Musculoskelet Neuronal Interact 2016; 16(1):24-32.
  34. Hoyer-Kuhn H, Semler O, Schoenau E. Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab 2014; 99(11):3954-3955.
  35. Li G, Jin Y, Levine MAH, Hoyer-Kuhn H, Ward L, Adachi JD. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings. Acta Paediatr 2018; 107(3):534-537.
  36. Ward L, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glorieux FH et al. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada. Calcif Tissue Int 2016; 98(6):566-572.
  37. Hoyer-Kuhn H, Stark C, Franklin J, Schoenau E, Semler O. Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab. Pediatr Endocrinol Rev 2017; 15(Suppl 1):123-129.
  38. Mrosk J, Bhavani GS, Shah H, Hecht J, Krüger U et al. Diagnostic strategies and genotype-phenotype correlation in a large Indian cohort of osteogenesis imperfecta. Bone. 2018 May;110:368-377.
  39. Palomo T, Vilaça T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2017 Dec;24:381-388.
  40. Holick MF, Hossein-Nezhad A, Tabatabaei F. Multiple fractures in infants who have Ehlers-Danlos/hypermobility syndrome and or vitamin D deficiency: A case series of 72 infants whose parents were accused of child abuse and neglect. Dermatoendocrinol. 2017 Feb 16;9:e1279768.
  41. Lindert U et al. Urinary pyridinoline cross-links as biomarkers of osteogenesis imperfecta. Orphanet J Rare Dis. 2015; 10: 104.